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Background: Low functional ovarian reserve (FOR) is at all ages associated with low testosterone (T) levels. Causes
are, however, unknown. We, therefore, investigate whether androgens with low FOR are associated with
non-specific immune system activation.
Methods: 322 infertile women with low and normal FOR (controls) were assessed with a broadly based immune
profile, which in previous studies has proven effective in differentiating infertile patients with and without immune
system activation. Patients were either immune-positive (greater than or equal to one positive tested parameter) or
immune negative (no positive test). 135 suffered from prematurely diminished FOR (POA/OPOI; < age 38), 155 from
physiologic diminished FOR due to age (DOR; > age 40), and 32 were controls (< age 38 with normal age-specific
FOR). Prevalence of immune-positive vs. negative was assessed in all 3 patient groups.
Results: Women with immune abnormalities, overall, demonstrated higher total T (TT, P = 0.004) and free T
(FT, P < 0.001) levels than those without. The three clinical and two immunologic-defined patient groups
demonstrated significant statistical interaction in mean TT (P = 0.008), with mean TT and FT in women with positive
immune findings being significantly higher in control than in POA/OPOI and physiologic DOR patients (all 4
differences P < 0.001). No such differences between the three groups were seen in women without immune
abnormalities.
Conclusions: In this study we used a definition of immune-positivity, which favors sensitivity over specificity,
resulting in significant numbers of false-positives but likely only few false-negatives. The study allows suggesting
the possibility of an immune system-derived androgen-production factor (APF), which maintains normal androgen
levels but is deficient in women with low FOR and immune system inactivity. Existence of such an APF would
suggest the presence of a still unknown functional adrenal autoimmune system.
Keywords: Androgens, Testosterone, Ovarian Reserve, Autoimmunity, In Vitro Fertilization* Correspondence: ykizawa@thechr.com
1Center for Human Reproduction, New York, NY 10021, USA
2Foundation for Reproductive Medicine, New York, NY 10021, USA
Full list of author information is available at the end of the article
© 2013 Gleicher et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Gleicher et al. Reproductive Biology and Endocrinology 2013, 11:58 Page 2 of 7
http://www.rbej.com/content/11/1/58Background
What in a woman constitutes total ovarian reserve (TOR)
has remained poorly defined [1,2]. Most investigators de-
scribe ovarian reserve (OR) as the sum of all remaining
follicles. This definition, however, includes in a majority
the non-growing pool of primordial follicles, which cannot
be reliably assessed [1,2]. Because total primordial follicles
appear to correlate to recruited follicles, and because anti-
Müllerian hormone (AMH) appears representative of small
growing follicles (after recruitment), AMH is now widely
considered the most accurate tool to assess TOR [1,3]. We
have come to call the pool of small growing follicles the
functional ovarian reserve (FOR) because it best reflects
what, a few months later, can be expected as oocyte yield
in an in vitro fertilization (IVF) cycle [2].
Small growing follicles in mouse studies have been dem-
onstrated dependent on androgen receptor (AR)-mediated
effects on granulosa cells [4], which, synergistic with fol-
licle stimulating hormone (FSH), lead to normal follicle
growth and oocyte development. Interruption of AR ef-
fects in granulosa cells, but not oocytes, leads to various
infertility-associated conditions [4]. Androgen sources are
adjacent theca cells in the ovary and the zona reticularis of
the adrenals.
That androgens at these stages of follicle develop-
ment may also be important in humans has been sug-
gested by observations in association with IVF [5,6] and
by reported improvements in fertility treatment out-
comes following supplementation of women at all ages
with low FOR with dehydroepiandrosterone (DHEA)
[7]. Indeed, the latter improvements have been demon-
strated to correlate well with improvements of testos-
terone levels after DHEA supplementation [8].
Based on these observations, we developed the hypoth-
esis that low FOR may represent an androgen deficiency
state, and recently presented confirmatory evidence [9].
Androgen deficiency is more profound in younger women
with prematurely diminished FOR (DFOR), i.e. premature
ovarian aging (POA), by others given the acronym occult
primary ovarian insufficiency (OPOI). The same study also
offered preliminary evidence that concomitantly low corti-
sol levels may accompany androgen insufficiency. Low
androgen in association with DFOR may, therefore, be ad-
renal as well as ovarian in etiology, mimicking in opposing
ways the hyperandrogenism and excessive follicle produc-
tion in some women with polycystic ovary syndrome
(PCOS) [9].
It, therefore, is tempting to hypothesize that PCOS and
POA/OCPOI reflect functionally opposing clinical condi-
tions of adrenals and ovaries in combination, similar to
hypo- and hyperthyroidism. Hypothyroidism is usually the
consequence of Hashimoto’s thyroiditis, associated with
anti-thyroglobulin and anti-thyroid peroxidase antibodies
[10], while autoantibodies to the thyrotropin receptorresult in hyperthyroidism [11]. Functional autoantibodies
in autoimmunity no longer are only limited to autoimmune
endocrine diseases [12]. They, therefore, appear more com-
mon in autoimmunity than previously assumed [13].
We in the past searched for but failed [14] or found only
statistically marginal data [15] in support of autoimmunity
in association with POA (OPOI). Those studies, however,
did not consider the patients’ androgen status. The re-
cently recognized importance of hypoandrogenism in de-
fining DFOR [9], now suggests that androgen levels may
be associated with immune system activation. As this
study will demonstrate, immune system activation, indeed,
appears to be associated with androgen levels.Methods
Study populations
This study involved the retrospective investigation of a
cohort of 322 infertile women for whom complete data
sets were available in the center’s electronic research
data bank of The Center for Human Reproduction –
New York, a private clinical and research center, special-
izing in reproductive endocrinology and infertility. They
were divided into three distinct groups: (i) 135 Women
with POA/OPOI (Group 1), defined as patients under
age 38 years with abnormally elevated age-specific FSH
[16] and/or abnormally low age-specific AMH [17]; (ii)
155 Women above age 40 years with age-dependent
DFOR, here simply described as physiologic DOR
(Group 2); and (iii) 32 control patients, defined as infer-
tility patients under age 38 with normal age-specific
FOR, based on FSH and AMH levels (controls). To cre-
ate a clear statistical distinction between POA/OPOI
and DOR patients, women between ages 38 and 40 years
were excluded from this study.Definition of immune system activation
Because of the reported high prevalence of autoimmune
abnormalities in infertile women and associated miscar-
riage risks [18,19], our center obtains an (auto)immune
panel in the initial investigation of every newly pre-
senting female infertility patient. Such a panel includes
the following: Antinuclear antibody, anti-phospholipid
antibodies (lupus anticoagulant, anti-cardiolipin, anti-
phosphatidylserine, β2-glycoprotein, for IgG, IgM and IgA
isotypes), anti-thyroid antibodies (anti-thyroglobulin, anti-
thyroid peroxidase), anti-adrenal antibody (21-hydroxy-
lase) and anti-ovarian antibodies (non-specific) as well as
total immunoglobulins in IgG, IgM, IgA and IgE.
The principal rationale for this panel is not the diagno-
sis of specific autoimmune conditions but the detection
of an activated autoimmune system, which may suggest
the presence of a polyclonal immune activation at a sub-
clinical level of autoimmune activity. Even with only a
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tests, a patient is, therefore, considered “affected.”
We fully recognize the non-specific nature of this defin-
ition of immune system activation, and the high rate of
expected false-positive patients it generates. This kind of
analysis, however, has proven itself in the past in a number
of studies [14,15,20-22] and, likely, to an acceptable de-
gree, precludes presence of autoimmunity in absence of
any detected laboratory abnormalities. We, thus, assume
relatively satisfactory negative predictability for immune
system activation from our immune screen, though at the
expense of a considerable degree of false positive results.
Utilizing these criteria 59.4 percent of control patients,
55.6 percent of POA/OPOI (Group 1) and 61.9 percent
of physiologic DOR (Group 2) patients were defined as
immunologically positive, a non-significant difference in
prevalence (P = 0.54). Furthermore, 34.4 percent of con-
trols, 26.7 percent of Group 1 and 33.5 percent of women
Group 2 patients (P = 0.40) demonstrated two or more
immune abnormalities, 9.4 percent of controls, 8.9 percent
of POA/OPOI and 18.1 percent of physiologic DOR pa-
tients demonstrated three or more immune abnormalities
(P = 0.06) (Figure 1). Prevalence of immune abnormalities,
thus, did not differ between controls and study groups,
though, not surprisingly considering their older age,
women with physiologic DOR (Group 2) did demonstrate
a trend towards more autoimmune abnormalities in com-
parison to the other two, younger patient groups, with up
to a 9 percent difference.
All tests were performed by commercial laboratory
testing in accordance with patient preference and insur-
ance requirements. A test was considered positive if theFigure 1 Prevalence of immune abnormalities in investigated
patient groups. X-axis demonstrates the number of immune
abnormalities per patient (range 1–3). The number of immune
abnormalities detected in in controls, POA/OPOI and DOR patients
did not differ. Women with DOR, however, demonstrated a trend
toward more ≥3 abnormalities in comparison to controls and
POA/OPOI patients (P = 0.06), with up to 9 percent difference.result fell outside of normal range, as defined by the pro-
cessing laboratory.
Androgen determinations
Androgen testing is also a routine part of every patient’s
initial evaluation and includes dehydroepiandrosterone
(DHEA), DHEA-sulfate (DHEAS), androstenedion, free
testosterone (FT), and total testosterone (TT). These tests
were also performed by commercial laboratories [9].
Statistical analyses
The Mann–Whitney U and ANOVA tests were used for
a majority of statistical analyses. All post hoc procedures
utilized the Holm Sidak test to determine significance.
Differences in distributions between categorical data
were compared using chi-square tests. All tests were 2-
tailed, with P < 0.05 considered statistically significant.
Institutional Review Board (IRB)
Since this study involved only the retrospective review of
anonymized electronic medical records in the center’s
research database, it required only expedited IRB review,
which was obtained. Our center’s patients at time of ini-
tial consultation sign an informed consent, which per-
mits the use of medical record data for research
purposes, as long as anonymity of patient identity and
confidentiality of the medical record is maintained.
Research personnel are also committed in writing to
confidentiality under federal HIPAA rules.
Results
Table 1 summarizes patient characteristics of all three
study groups. As can be seen, mean ages were in con-
trols 33.1 ± 3.7 years, in POA/OPOI women 34.5 ± 3.2
and in physiologic DOR, 43.2 ± 2.4 years (Sidak test,
controls vs. DOR and POA/OPOI vs. DOR, both P <
0.001; controls vs. POA/OPOI P = 0.04). The groups did
not differ in body mass index (BMI).
They, however, did significantly vary in OR parame-
ters: FSH was 6.3 ± 2.5 mIU/mL in controls, 13.4 ± 14.2
mIU/mL in POA/OPOI and 17.8 ± 13.1 mIU/mL in
physiologic DOR patients (Sidak test, controls vs. POA/
OPOI, P = 0.02; controls vs. DOR, P < 0.001; POA/ OPOI
vs. DOR P = 0.02). AMH values were in controls 3.3 ±
2.1 ng/mL, in POA/OPOI 0.9 ±1.1 ng/mL and in DOR
patients 0.3 ± 0.3 ng/mL (Sidak test, all 3 groups P <
0.001 in comparison to each other).
Adjusted for BMI and age, DHEA, DHEAS did not
differ amongst women with or without presumed auto-
immunity. Women with immune abnormalities, how-
ever, demonstrated overall higher TT and FT levels than
women without such abnormalities (Sidak test, P = 0.004
and P < 0.001, respectively).
Table 1 Patient characteristics of controls, POA/OPOI and DOR patients
POA/OPOI DOR Controls P value (Sidak test)
N 135 155 32
Age (years) 34.5 ± 3.21,2 43.2 ± 2.41,3 33.1 ± 3.72,3 10.001, 20.04, 30.001
BMI (kg/m2) 24.0 ± 4.8 24.3 ± 5.0 22.0 ± 5.5
FSH (mIU/mL) 13.4 ± 14.24,5 17.8 ± 13.14,6 6.3 ± 2.55,6 40.02, 50.02, 60.001
AMH (ng/mL) 0.9 ± 1.17,8 0.3 ± 0.37,9 3.3 ± 2.18,9 70.001, 80.001, 90.001
Race n (%)
Caucasian 90 (66.7) 119 (76.8) 19 (59.4)
African 16 (11.9) 18 (11.6) 4 (12.5)
Asian 29 (21.5) 18 (11.6) 9 (28.1)
Values are presented as means ± SD.
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presumed immune activation, differentiating between
women with no and one or more immune abnormalities,
there was a statistically significant interaction in mean TT
[F (2,240) = 4.89, P = 0.008]. Post hoc comparisons, using
the Sidak test, suggested that mean TT, stratified for im-
mune activation, in women with positive autoimmunity
was significantly higher in controls (M = 40.2, SD = 24.1)
than in women with POA/OPOI (M= 23.6, SD = 7.8, P <
0.001) and in women with physiologic DOR (M= 26.6,
SD = 14.5, P < 0.001) (Figure 2a).
The same was noted in association with mean FT levels:
Interaction between three patient groups and two im-
munologic definitions was [F (2, 207) = 9.47, P < 0.001];
and, amongst autoimmune-positive women controls (M=
3.9, SD = 3.1) demonstrated significantly higher FT than
POA/OPOI patients (M = 2.1, SD = 1.0; P < 0.001) and
women with physiologic DOR (M= 1.9, SD = 1.1; P <
0.001) (Figure 2b).
These statistical differences in testosterone between
control patients and both study groups were, however,
not seen in women without evidence of autoimmunity
(Figure 2a,b). None of the investigated immune parame-
ters, in isolation, were statistically associated with andro-
gen levels, including anti-adrenal and anti-ovarian
antibodies.
Discussion
This study demonstrates statistical associations between
immune system activation and androgen levels in infer-
tile women with normal FOR and absence of both in as-
sociation with POA/OPOI and age-dependent DFOR.
The results, however, do not necessarily demonstrate the
associations we expected. Data confirmed our earlier re-
port that women with POA/OPOI and physiologic DOR,
in principle, demonstrate lower testosterone levels than
control patients with normal OR [9]. The study, how-
ever, also demonstrated higher testosterone levels with
than without immune system activation. Moreover,amongst women with immune system activation, andro-
gen levels were higher in women with normal FOR
(controls) than in those with DFOR (I.e., POA/OPOI
and physiologic DOR). Indeed, POA/OPOI and DOR
patients, whether demonstrating signs of immune acti-
vation or not, demonstrated similar androgen levels as
immunologically negative controls (Figure 2).
These observations suggests that in most young women
with normal FOR a degree of immune activation exists, as-
sociated with normal to mildly elevated T levels (Figure 2),
while in association with low FOR, whether due to POA/
OPOI or physiologic DOR, T levels are lower in absence of
evidence of immune system activation. Immune system ac-
tivation, thus, appears in some fashion associated with nor-
mal to mildly elevated androgens, while in absence of such
immune system activation androgens plunge.
This observation may be interpreted as suggesting that
immune system activation is associated with presence of
an androgen-producing factor (APF), an in itself interest-
ing observation, considering that induction of tolerance
with implantation of the paternal semi-allograft, unques-
tionably, requires some form of maternal immune system
activation. Considering the relatively small number of pa-
tients in each of the three studied patient populations, our
data, however, of course, require further confirmation.
Androgens are generally believed immunosuppressive
[23,24], though also have been suggested to have an
immuno-modulatory effect, either immuno-enhancing
or -suppressive [25]. Assuming immune system-induced
increases androgen levels, then such immuno-modulatory
effects of androgens may be able to feed back, and self-
control androgen production by adrenals and/or ovaries.
Anti-adrenal autoimmune responses in Addison’s dis-
ease and autoimmune ovarian insufficiency are, indeed,
similar in that both are IgG1 dominated and predomin-
antly of Th 1 type [26]. Albertini, only recently, described
the ovary, “as something of an immunological hotspot,”
since many genes, recently implicated in ovarian aging,
are associated with immune pathways [27].
Figure 2 Testosterone levels in patients with and without presumed immune activation. A demonstrates TT and B FT levels; both were,
overall, among women with autoimmunity significantly elevated (P = 0.004 and P < 0.001, respectively) but in women with POA/OPOI and DOR
significantly diminished (both P < 0.001) in comparison to controls. Women without evidence of immune system activation, in contrast, overall,
demonstrated lower androgen levels (as noted above) and did not differ in either TT or FT between controls and POA/OPOI and physiologic
DOR patients.
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women with POA/OPOI and physiologic DOR the
immune system’s ability to produce APF is lost. As a
consequence, T levels are low (Figure 2). Two possible
explanations come to mind: either the production of
APF is interrupted or the effects of APF are blocked.
Our results more likely suggest diminution of APF pro-
duction, since blockage of APF, likely, would have to in-
volve evidence of increased immune system activities,
the opposite of what was observed.
Assuming such an androgen-regulation process in ad-
renals and ovaries, one also has to assume the possibility
of APF overproduction. Such overproduction then could
be expected to result in excessive androgen levels and,
hypothetically, an ovarian PCOS- like phenotype Such
phenotypes, of course, can be either hyper- or normo-androgenic [28]. PCOS and DOR may, therefore, repre-
sent opposing extremes of, possibly, immune-mediated
effects on adrenals and/or ovaries [9,13].
We are not the first to suggest such an autoimmune
etiology for at least some cases of PCOS [29,30]. Interest-
ingly, González et al. just recently reported that hyper-
androgenism apparently exerts anti-inflammatory effects
on women with PCOS [31]. Androgen effects on early
stages of follicle maturation are AR-mediated [4]. AR-
activation in benign prostatic hyperplasia was only recently
demonstrated produce anti-inflammatory effects [32].
Our findings raise a multitude of interesting follow up
questions, with the first being how an immune process,
selectively, can be associated with higher androgen
levels? This study does not offer an answer, but adrenals
produce the majority of a woman’s DHEA, the basic
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association with PCOS [28], at least a portion of ob-
served testosterone levels, therefore, can be expected to
be consequence of adrenal processes.
Immune-driven stimulation of androgen production in
the zona reticularis of adrenals is conceivable. Immune-
driven endocrine processes are often antibody-mediated
[34], and even organ-specific anti-glandular autoim-
munity is now increasingly recognized associated with
systemic autoimmune effects [35]. In association with
Addison’s disease, an autoantibody to 21-hydroxylase, a
cytochrome P450 enzyme, is diagnostic [36]. Autoanti-
bodies to other adrenal steroidogenic enzymes have also
been described [37,38]. The practically complete absence
of anti-21-hydroxylas antibodies in here presented pa-
tients (unpublished data), however, suggests that in this
study observed immune activation is distinct from
Addison’s disease.
Functional autoantibodies can be either suppressive or
enhancing and have also been described in non-endocrine
autoimmune diseases [12]. This led us to suggest that such
regulatory autoantibodies may represent a more frequent
characteristic of autoimmune diseases than is generally ap-
preciated [13]. This study now allows for the possibility of
an autoantibody network, which controls androgen pro-
duction by the adrenal zona reticularis of and/or the ovar-
ian theca, representing APF.
Women are especially prone to autoimmune diseases,
especially towards autoimmune endocrinopathies and
combinations of multiple autoimmune endocrinopathies,
autoimmunity towards the thyroid gland being the most
frequent [39].
We recently reported specific genotypes and sub-
genotypes of the FMR1 gene, associated with distinct
ovarian aging patterns. The so-called het-norm/low sub-
genotype appears associated with an ovarian PCO-like
phenotype at young age, which rapidly depletes follicles,
leading to early DFOR often at relatively young ages
[21]. Whether the early stages of PCO-like phenotype
are associated with hyperandrogenism is unknown but
the same sub-genotype of FMR1 was recently also dem-
onstrated to convert DHEA to TT less efficiently than
other FMR1 genotypes did [8]. The specific reason why
women with het-norm/low FMR1 convert so poorly is
unknown but it is interesting to note that this sub-
genotype is also highly associated with autoimmune risk,
while its counterpart, the het-norm/high sub-genotype, is
protective against autoimmunity [21].
In conclusion, this study reports first supportive evi-
dence for a, possibly, immune system-associated androgen
production process, likely primarily located in adrenals
and/or ovaries. We hypothesize that this process, in ana-
logy to immune processes in other endocrine organs, may
be autoantibody-driven. For the interested reader a recentreview on the impact of endocrine autoimmune diseases
on female fertility offers additional insights [40].
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